Business Wire

1. ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery With AI And First-Principles Innovation 1/17/2025

   ImmunoPrecise Antibodies Ltd. today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development.

2. Zai Lab Announces Acceptance Of New Drug Application For KarXT For The Treatment Of Schizophrenia 1/17/2025

   Zai Lab Limited today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults.

3. Arrowhead Pharmaceuticals Announces Acceptance Of New Drug Application By U.S. FDA Of Plozasiran For The Treatment Of Familial Chylomicronemia Syndrome 1/17/2025

   Arrowhead Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease.

4. Kardigan Launches With Industry-Leading Team To Modernize Cardiovascular Drug Development With Late-Stage Portfolio Of Personalized Medicines 1/10/2025

   Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve.

5. Zai Lab Announces Strategic Partnership With MediLink Therapeutics To Develop A Novel LRRC15 Antibody-Drug Conjugate 1/9/2025

   Zai Lab Limited today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.

6. Vividion Therapeutics Acquires Tavros Therapeutics To Expand Functional Genomics Capabilities And Boost Drug Discovery Platform 1/8/2025

   Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company.

7. Acellera Therapeutics Unveils AceForce 1.0: A Novel Family Of Next-Generation Neural Network Potential Accelerating Drug Discovery 1/7/2025

   Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of AceForce 1.0, its groundbreaking neural network potential (NNP) model designed to deliver quantum-level accuracy for predicting atomic interactions—an essential factor in identifying promising drug candidates earlier and more efficiently.

8. AliveGen Receives FDA Orphan Drug Designation For ALG-801 For Pulmonary Arterial Hypertension 1/7/2025

   AliveGen USA Inc. (AliveGen), a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the treatment of pulmonary arterial hypertension (PAH), a rare, serious, and life-threatening condition characterized by high blood pressure in the lung arteries that can lead to right-sided heart failure.

9. Biocytogen And Acepodia Join Forces To Advance Bispecific Antibody And Dual-Payload ADCs For Treating Complex Tumors 1/7/2025

   Biocytogen and Acepodia today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.

10. Star Therapeutics Receives FDA Fast Track Designation For VGA039 In Von Willebrand Disease (VWD) 1/6/2025

    Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VGA039 in von Willebrand disease (VWD).